Human Blood-Derived Mesenchymal Stem Cell to Repair Cartilage Defect
The present invention provides a method of isolating, culturing, proliferating and maintenance of the mesenchymal stem cells (MSCS) derived from human peripheral blood. The peripheral blood is a (clinically accessible) potential source of MSCS. The method used in the present invention is reliable, involved minimal invasive procedures, in less time, and is cost-consuming. MSCS is able to isolate, purify, greatly multiply and differentiate into cartilage cells for the use of treating cartilage defects. Thus, the present invention also provides a potential cell therapy to repair cartilage defects from the human blood-derived chondrogenic-MSCS.
Contact person for this offer:
ChM Dr. Lee Ching Shya, PhD (Dual), RTTP
Technology Transfer Manager
Tel: +603-7967-7351/ 013-2250151